<DOC>
	<DOCNO>NCT02024932</DOCNO>
	<brief_summary>The purpose study determine BVS857 safe , tolerable increase thigh muscle thickness patient spinal bulbar muscular atrophy ( SBMA ) .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy BVS857 Patients With Spinal Bulbar Muscular Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Muscular Disorders , Atrophic</mesh_term>
	<mesh_term>Bulbo-Spinal Atrophy , X-Linked</mesh_term>
	<criteria>Genetic diagnosis SBMA symptomatic muscle weakness Able complete 2 minute time walk Serum IGF1 level less equal 170 ng/mL Medically treat diabetes mellitus know history hypoglycemia History Bell 's palsy Treatment systemic steroid &gt; 10 mg/day ( equivalent dose ) ; androgens androgen reduce agent ; systemic beta agonist ; muscle anabolic drug within previous 3 month History cancer , nonmelanomatous skin cancer Retinopathy Papilledema Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>